Skip to main content

Table 3 Prognostic Factors for Progression-free survival

From: PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

  Hazard Ratio (95% CI) P value
Performance (0 vs 1) 0.74 (0.39–1.44) 0.38
Number of previous chemotherapy (1 vs 2–3) 0.67 (0.29–1.57) 0.36
Sex (female vs male) 1.27 (0.65–2.49) 0.49
Age (≤48 years vs > 48 years) 1.69 (0.86–3.30) 0.12
ECOG (0–1 vs 2) 0.74 (0.39–1.44) 0.38
Grade (I vs II-III) 1.22 (0.43–3.45) 0.77
Histologic subtype
(leiomyosarcoma and synovial sarcoma
vs other subtypes*)
1.17 (0.49–2.06) 0.95
Locoregional disease (yes vs no) 1.10 (0.60–2.03) 0.75
Liver metastases (yes vs no) 0.75 (0.22–2.58) 0.65
PD-L1 expression (positive vs negative) 2.77 (1.45–5.56) 0.006
TIL (high vs low) 1.41 (0.83–2.37) 0.197
  1. *other subtypes: undifferentiated pleomorphic sarcoma, angiosarcoma, myofibroblastic sarcoma, MPNST (malignant peripheral nerve sheath tumor), ASPS (Alveolar soft part sarcoma), epithelioid sarcoma, DSRCT, osteosarcoma, liposarcoma, rhabdomyosarcoma, and PECOMA
  2. Abbreviation: Eastern Cooperative Oncology Group (ECOG), tumour infiltrating lymphocytes (TILs)